Vol.

No.

May 08, 2026May 08, 2026

DOWNLOAD THE PDF

Cover Story

Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC

AstraZeneca’s application for camizestrant, a next-generation oral selective estrogen receptor degrader, or SERD, in metastatic breast cancer might have seemed set to sail smoothly through the FDA approval process.

Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel

By Paul Goldberg

Letter To The Editor

J. Craig Venter’s work was foundational to cancer advancement of the past 25 years

By Joyce Ohm

Collaborative work behind the scenes makes cancer breakthroughs possible

By Annaliese Daniels

Podcast

Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)

Cancer Policy

Trump changes pick for Surgeon General, nominating Nicole Saphier

Katherine Szarama steps in as CBER acting director, replacing Prasad

In Brief

Chris Li named senior vice president and director of the Public Health Sciences Division at Fred Hutch

Amelia Jernigan named cancer service line director for LCMC Health

American Cancer Society names four members to Board of Directors

Thomas Buchholz receives the American Radium Society’s Gold Medal Award

Aimee Johnson named chief marketing officer of Parker Institute

Pershing Square Sohn Cancer Research Alliance doubles funding commitment, awarding 13 innovators

Hayan Lee wins the Arima Genomics Multi-Omics Grant

Funding Opportunities

FDA’s OCE announces funding opportunity in ultra-rare cancers

Clinical Roundup

American College of Radiology approves first ever Practice Parameter for Imaging Artificial Intelligence

Electric jolt technique offers possible avenue for early detection of pancreatic cancer, OHSU-led study finds

Hopkins physicians achieve 95% cure rate for sickle cell disease with bone marrow transplant

Mayo and Stanford researchers develop first blood test to map tumor “neighborhoods,” improving prediction of therapy response

University of Cincinnati achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy

Cancer metabolism linked to DNA replication errors, UTSW study finds

Inherited long telomeres may drive broad risk for lymphoid cancers, Hopkins-led study finds

Drugs & Targets

FDA permits expanded access for investigational pancreatic cancer drug daraxonrasib

FDA approves Jakafi XR tablets for myelofibrosis, polycythemia vera, and graft-versus-host disease

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 41 - November 06, 2026